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Abstract
The formulation of water insoluble organic compounds into nanoparticles has become a widely
established method for enhancing the delivery and efficacy of cancer therapeutics. Therefore, a
comparable approach when applied to water insoluble inorganic compounds should also promote
similar advantages. Herein, we have successfully formulated insoluble iodinated cisplatin (CDDP-
I) into a LPI NPs (lipid-coated iodinated CDDP nanoparticles). Two separate microemulsions
were combined, each containing a precursor for the synthesis of CDDP-I. The resulting CDDP-I
precipitate was then coated with an anionic lipid and dispersed in water with the help of an
additional lipid. This method allows us to effectively encapsulate CDDP-I and was able to achieve
a considerable drug loading of 82 wt%. Administered LPI NPs demonstrated high level
accumulation in tumor tissues and exhibited an anti-cancer activity comparable to free CDDP in
two melanoma xenograft models without inducing nephrotoxocity. The benefits offered through
this delivery formulation are not unique to CDDP-I, as this versatile platform may be extended to
the formulation of other inorganic compounds that are both water and oil insoluble into
nanoparticles for superior anticancer efficacy.
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1. Introduction
The application of cisplatin (CDDP), an established anticancer drug, is hampered by severe
side effects such as neuro- and nephro-toxicity, which limit the maximum tolerated dose
(MTD) of cisplatin [1, 2]. To overcome these shortcomings, derivatives incorporating more
stable leaving groups, such as carboplatin and oxaliplatin, have been synthesized to reduce
side effects. Yet, such modifications inadvertently diminish the efficacy [3, 4]. Another
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potential strategy has been to alter the halide leaving groups [5]. After this alteration,
bromide retains activity and exhibits potent anti-tumor efficacy while iodinated CDDP
(CDDP-I) is ineffective, probably due to its insolubility [5, 6].
Nanoparticulate formulations have been developed to enhance the accumulation of CDDP in
tumors through the enhanced permeability and retention (EPR) effect while reducing side
effects through a restricted drug distribution [7, 8]. Unlike paclitaxel, a water insoluble but
oil soluble anti-tumor drug, CDDP-I, is insoluble in any organic solvent and cannot be
formulated into nanoparticles (NP) or liposomes. However, formation of CDDP-I
nanocrystals may be achieved using “top-down” technology, which involves breakdown of
large drug particles through a milling process [9–11]. Most nanocrystal formulations are
administered orally even though nanocrystals dissociate quickly in the blood stream. Taking
advantage of this property, we aim to develop a CDDP-I formulation for intravenous
administration.
In previous work, CDDP was used to construct LPC NPs [12] in a microemulsion reactor
using the CDDP precursor and potassium chloride (KCl). Drug loading efficiency for this
NP formulation was high (80 ± 5 wt%). CDDP-I was synthesized through a reaction
between potassium iodine (KI) and the CDDP precursor in a microemulsion to make cores
which were dispersed in water (Scheme 1). Dioleoyl phosphatydic acid (DOPA), an anionic
lipid, was used to stabilize the CDDP-I cores, which were further dispersed using an outer
leaflet lipid layer to obtain LPI NPs (lipid-coated iodinated CDDP nanoparticles). Cell
toxicities of LPI NPs and release of CDDP-I from LPI NPs were evaluated then. Tumor
accumulation, anti-tumor effect and safety of LPI NPs were also investigated.
2. Materials and methods
2.1. Materials
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Dulbecco's Modified
Eagle Medium (DMEM), L-glutamine, penicillin G sodium, streptomycin and fetal calf
serum were purchased from Gibco®. DSPE-PEG-AA was synthesized in our laboratory as
previously reported [13]. 1-Hexanol was purchased from Alfa Aesar. Igepal®CO-520,
triton™ X-100, cyclohexane, CDDP and silver nitrate were obtained from Sigma-Aldrich
(St Louis, MO) without further purification. Pluronic P85 was purchased from BASF
Corporation (North Mount Olive, NJ).
2.2. Cell Lines
A375M and 1205Lu cells were cultured in DMEM medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 20 mM of L-glutamine, 100 U/mL of penicillin G
sodium, and 100 mg/mL of streptomycin at 37 °C in an atmosphere of 5% CO2 and 95% air.
2.3. Synthesis of cis-[Pt(NH3)2(H2O)2](NO3)2 Precursor
Briefly, AgNO3 (66.2 mg, 0.39 mmol) was added to a suspension of CDDP (60 mg, 0.20
mmol) in 1.0 mL water. The mixture was heated at 60 °C for 3 h and then stirred overnight
in a flask protected from light with aluminum foil. The mixture was then centrifuged at
Guo et al. Page 2






















16,000 rpm for 15 min to remove the AgCl precipitate. The solution was filtered using a 0.2
µm syringe filter. The concentration of cis-[Pt(NH3)2(H2O)2](NO3)2 was measured using
ICP-MS and adjusted to 200 mM.
2.4. Preparation of LPI NPs
The synthesis of LPI NPs is described in Scheme 1. First, 100 µL of 200 mM cis-
[Pt(NH3)2(H2O)2](NO3)2 was dispersed in a solution composed of a mixture of
cyclohexane/Igepal®CO-520 (71:29, V:V) and cyclohexane/triton-X100/hexanol (75:15:10,
V:V:V) to form a well-dispersed, water-in-oil reverse micro-emulsion. Another emulsion
containing KCl was prepared by adding 100 µL of 800 mM KI in water into a separate 8.0
mL oil phase. One hundred µL of DOPA (20 mM) was added to the CDDP precursor phase
and the mixture was stirred. Twenty min later, the two emulsions were mixed and the
reaction proceeded for another 30 min. Following the reaction, 16.0 mL of ethanol was
added to break the micro-emulsion and the mixture was centrifuged at 12,000 g for at least
15 min to remove the cyclohexane and surfactants. After being extensively washed with
ethanol 2–3 times, the pellets were re-dispersed in 3.0 mL of chloroform and stored in a
glass vial for further modification.
To prepare the final NPs, 1.0 mL of CDDP-I core, 100 µL of 20 mM 1,2-dioleoyl-3-
trimethylammonium-propane (chloride salt) (DOTAP)/cholesterol (molar ratio 1:1) and 50
µL of 10 mM DSPE–PEG-2000 or DSPE–PEG–AA were combined. After evaporating the
chloroform, the residual lipids were dispersed in 1.0 mL of d-H2O.
2.5. Characterization of NPs
The zeta potential and particle size of LPI NPs were determined using a Malvern ZetaSizer
Nano series (Westborough, MA). TEM images were acquired using a JEOL 100CX II TEM
(JEOL, Japan). The LPI NPs was negatively stained with 2% uranyl acetate. The drug-
loading capacity and platinum content were measured using inductively coupled plasma
mass spectrometry (ICP-MS).
2.6. Cell Toxicity Assay
A375M and 1205Lu cells were seeded in 96-well plates at a density of 2000 cells/well and
incubated in a 10:1 ratio of DMEM and FBS containing 100 U/mL penicillin, and 100
mg/mL streptomycin for 20 h. The medium was then removed and replaced by Opti-MEM
containing CDDP or LPI NPs. Forty-eight hours later, a CellTiter 96 AQueous One Solution
Cell Proliferation Assay kit (Promega, Madison, WI) containing the tetrazolium compound
MTS was used to assay cell viability according to the manufacturer's protocols. IC50 values
were calculated using Graphpad Prism 5 (Graphpad Software Inc.).
2.7. Cellular Uptake
A375M cells were seeded in 24-well plates at a density of 3×104 cells per well and
incubated for 20 h in 10% FBS of DMEM containing 100 U/mL penicillin, and 100 mg/mL
streptomycin. The medium was then removed and replaced by 100 µM of Opti-MEM
containing CDDP or LPI NPs. All transfections were performed in triplicate. After
incubation for 4 h at 37 °C in a 5% CO2, humidified atmosphere, the medium was aspirated.
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Cells were then washed and lysed in order to determine their uptake of NPs. The amount of
Pt in cells was measured using ICP-MS.
2.8. In Vitro Drug Release
A suspension of LPI NPs containing 200 µg Pt in 0.1 wt% P85, 50% FBS or PBS was
incubated at 37 °C in a shaker at 300 rpm. During different time points, the corresponding
samples were centrifuged at 16,000 g for 20 min and the platinum released into the
supernatant liquid was measured using ICP-MS.
2.9. Biodistribution
The mice were administered a single dose of 1.0 mg/kg Pt CDDP and LPI NPs. Each group
contained five mice, which were sacrificed 4 h following injection. Tissue samples were
digested by concentrated nitric acid overnight at room temperature and processed according
to the procedure reported previously in the literature. The concentration of Pt was measured
using ICP-MS.
2.10. In Vivo Anti-tumor Efficacy Evaluation
Animals were maintained in the Center for Experimental Animals (an AAALAC accredited
experimental animal facility) at the University of North Carolina. All procedures involving
experimental animals were performed in accordance with the protocols approved by the
University of North Carolina Institutional Animal Care and Use Committee and conformed
to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23,
revised 1985). Female athymic nude mice, 5–6 weeks old and weighing 18–22 g, were
supplied by the University of North Carolina animal facility. 1205Lu and A375M xenograft
tumors were developed through subcutaneous injection of approximately 5 million tumor
cells. Two mg/kg and 1.0 mg/kg of Pt were administered weekly by intravenous (IV)
injection for treatment of 1205Lu and A375M tumor bearing mice respectively.. Both, tumor
growth and body weight were monitored. Tumor volume was calculated using the following
formula: TV = (L × W2)/2, with W being smaller than L. Finally, mice were sacrificed by
CO2 asphyxiation. Tumors were collected after treatment, fixed with formalin and processed
for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.
2.11. TUNEL Assay
Tumors were fixed in 4.0% paraformaldehyde (PFA), paraffin-embedded and sectioned at
the UNC Lineberger Comprehensive Cancer Center Animal Histopathology Facility. To
detect apoptotic cells in tumor tissues, a TUNEL assay, using a DeadEndTM Fluorometric
TUNEL System (Promega, Madison, WI), was performed, following the manufacturer’s
protocol. Cell nuclei, which were stained with green fluorescence, were defined as TUNEL-
positive nuclei. TUNEL-positive nuclei were monitored using a fluorescence microscope
(Nikon, Tokyo, Japan). The cell nuclei were stained with 4, 6-diaminidino-2-phenyl-indole
(DAPI) (Vectashield, Vector Laboratories, Inc., Burlingame, CA). To quantify TUNEL-
positive cells, green-fluorescence-positive cells were counted in three images taken at 40×
magnification.
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2.12. Detection of Pt-DNA adducts
The CDDP-DNA adducts were detected using anti-CDDP modified DNA antibodies
[CP9/19] (Abcam, Cambridge, MA). The sections were incubated with a 1:250 dilution of
anti-CDDP modified DNA antibody [CP9/19] at 4 °C overnight followed by incubation with
FITC-labeled goat anti-(rat Ig) antibody (1 : 200, Santa Cruz, CA) for 1 h at room
temperature. The sections were also stained by DAPI and covered with a coverslip. The
sections were observed using a Nikon light microscope (Nikon Corp., Tokyo, Japan).
2.13. Toxicity and Pathology Studies
For liver and renal function experiments, the levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and blood urea nitrogen in the serum (BUN) were
measured. Major organs were collected after therapeutic treatment and were formalin fixed
and processed for routine H&E staining using standard methods. Images were collected
using a Nikon light microscope (Nikon).
2.14. Statistical Analysis
Quantitative data were expressed as mean ± SEM. The analysis of variance is completed
using a one-way ANOVA.
3. RESULTS AND DISCUSSIONS
3.1. Preparation and characterization of LPI NPs
Due to the insolubility of CDDP-I in water and organic solvents, current drug loading
methods including remote loading, double emulsion and nanoprecipitation, cannot be used
to formulate CDDP-I into NPs. CDDP and its derivatives are inorganic, poorly soluble and
usually synthesized by mixing the precursor and leaving group-donating compounds, which
both are water-soluble. These properties make CDDP and its derivatives unique to other
anti-cancer drugs. Microemulsion methods have been successfully utilized to synthesize
inorganic nanoparticles, such as silver chloride and calcium phosphate NPs, using a
nanoprecipitation process. Therefore, we hypothesize that NPs containing CDDP-I with a
controllable size range can also be synthesized in-situ using the microemulsion method.
DOPA, known to bind to metal ions such as calcium and platinum, was used to stabilize the
CDDP-I precipitate and permitted control over the nanoprecipitates’ size. The surfactants
Igepal and Triton X-100 were used for a similar purpose [14–16]. Without DOPA, the
formation of the cores was not well controlled and large aggregates were formed after
demulsification with ethanol. DOPA coated cores are water insoluble but soluble in non-
polar solvents, such as hexane, chloroform and tetrahydrofuran. Thus, to disperse CDDP-I
cores into water, an outer leaflet layer of 1,2-dioleoyl-3-trimethylammonium-propane
(chloride salt) (DOTAP), cholesterol, DSPE-PEG and DSPE-PEG-AA were coated onto the
CDDP-I cores to form stable LPI NPs.
Hydrated LPI NPs were purified through centrifugation at 10,000 g for 10 min. Drug
loading was approximately 82 ± 3 wt%, which was the highest compared to other platinum
drug based formulations, and the yield was approximately 42 ± 6%. The size of LPI NPs
was examined by TEM and DLS. Cores were about 30–35 nm in diameter (Fig. 1A). Uranyl
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acetate staining of TEM images revealed a diameter of about 40 nm (Fig. 1B), a little
smaller than the hydrodynamic diameter (40–45 nm) obtained by dynamic light scattering
(Fig. 1C). Here, we revealed a concept of formulating an insoluble drug using a hydrophobic
lipid coating. Hydrophobic CDDP-I cores can assemble with an outer leaflet lipid, and
possibly also with amphiphilic copolymer, such as PEG-PLGA. This provides the
opportunity for CDDP-I to be co-encapsulated alongside other hydrophobic drugs.
3.2. Cell toxicities of LPI NPs in 1205Lu and A375M melanoma cells
Following microemulsion synthesis and nanoparticulate formulation of CDDP-I, we
proceeded to evaluate the anti-tumor activity of LPI NPs in vitro. CDDP was chosen as a
control for comparison due to the insolubility and ineffective suspension of CDDP-I. LPI
NPs demonstrated a greater efficacy for the inhibition of 1205Lu cells than CDDP alone and
had a comparable toxicity against A375M cells (Fig. 2A). These results suggest that LPI
NPs are highly toxic to melanoma cancer cells when appropriately formulated. The potent
effects of LPI NPs observed in vitro might be attributed to the enhanced uptake of the NPs
(Fig. 2B).
3.3. In vitro release of the CDDP-I from LPI NPs
In PBS, 50% of the CDDP-I loaded in LPI NPs was released within approximately 80 hours
(Fig. 3). The slow kinetics was most likely attributed to the low aqueous solubility and
barrier caused by the lipid membrane. To facilitate the release of platinum from LPI NPs, a
surfactant, Pluronic® P85, was used to lyse the lipid bilayer. Even a small amount (0.1 wt%)
of P85 reduced the release time to approximately 2.5 h from 80 h. This release profile is
very similar to the release of doxorubicin from Doxil®, whose interior phase contains
crystalline doxorubicin [17]. To further investigate the release mechanism and mimic
physiological conditions, a release experiment was performed in FBS medium containing
lipases. The release was accelerated 50% of the CDDP-I released in just 6 h. LPI NPs are
relatively stable in PBS and can release CDDP-I in the presence of lipase suggesting that
NPs remain intact prior to tumor cell uptake.
Traditional liposomal CDDP formulations, such as STEALTH® formulation loaded with
CDDP (SPI-077), are characterized by slow drug release rates, which significantly limit the
formulation’s efficacy. In vitro release experiments indicated a negligible release (<10%) of
platinum from SPI-077 liposomes after a one-week incubation in serum [18, 19].
Furthermore, in vitro cytotoxicity assays indicated that SPI-077 had reduced cytotoxic
activity over CDDP, and in vivo experiments failed to indicate any superior anti-tumor
activity of the liposomal formulation over A375M tumors. However, CDDP-I formulated in
LPI-NPs were able to release 50% of platinum within approximately 6.0 h in the presence of
50% serum, a process which was further accelerated when the lipid bilayer was lysed by
Pluronic® P85. Adequate release permitted LPI NPs to show superior activity over free
CDDP both in vitro and in vivo in A375M and 1205Lu melanoma xenograft models as
discussed below.
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The biodistribution of free CDDP versus LPI NPs in A375M tumor-bearing mice was then
evaluated. Twenty-four h post IV injection, the CDDP concentration was measured by ICP-
MS. Approximately, 9.5% of the injected dose (ID) per gram of LPI NPs accumulated in
tumors; significantly higher than the 1.2% observed with free CDDP (Fig. 4). LPI NPs
accumulated in the liver and spleen with a similar biodistribution profile to LPC NPs [11].
These organs are expected to be macrophage rich and sites of nanoparticle clearance. LPI
NPs showed comparable accumulation to free CDDP in the kidney, where nephrotoxicity
was often observed for CDDP treated mice. LPI NPs showed minimal accumulation in the
heart.
3.5. In vivo anti-tumor efficacy of LPI NPs on 1205Lu and A375M xenograft tumor
In vivo IV administered LPI NPs had a greater anti-tumor effect than free CDDP in A375M
at 1 mg/kg Pt and inhibited the growth of 1205Lu tumors at 2 mg/kg Pt. Significant weight
loss was not observed in treated animals (data not shown). Previously, we have shown that
LPC NPs, similar formulation to LPI NPs, exhibited a neighouring effect in killing A375M
tumor [11]. Neighouring effect may be also true for LPI NPs, which induced significant
tumor inhibition in A375M tumor. However, the neighouring effect was not previously
observed in 1205Lu tumor. Differences in the tumor microenvironment may also contribute
to the less efficient anticancer efficacy of LPI NPs in 1205Lu tumors.
3.6. Cytotoxic effects of LPI NPs in A375M tumor cells
The cytotoxicity of LPI NPs on A375M tumor cells was determined through terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and staining for Pt-DNA
adducts. The TUNEL assay was used detect DNA fragmentation occurring during apoptosis.
Following LPI NPs administration, 15.8% of A375M tumor cells were apoptotic. To
indicate that LPI NPs released CDDP-I to inhibit tumor proliferation through the formation
of Pt-DNA adducts, tumor sections were stained with a Pt-DNA adduct-specific antibody
and confirmed the formation of CDDP-DNA adducts in treated tumors (Fig. 6B). It was
observed that the formation of CDDP-DNA adducts was present in 11.9% of tumor cells.
Therefore, LPI NPs successfully released active Pt drugs to induce apoptosis in tumor cells
through the formation of Pt-DNA adducts. Furthermore data from the in vitro release study
indicated that release rate could be greatly enhanced in the presence of a surfactant, e.g. P85,
to surpass that of the effect of FBS (Fig. 3). This result suggests that the primary factor
limiting faster drug release was the lipid bilayer on the surface of the drug precipitate, and
not the solubility of the encapsulated drug. It is conceivable that successful drug release
inside tumor cells was facilitated by lysosomal lipases, which act to destroy the lipid bilayer
when LPI NPs were endocytosed by tumor cells. The released drug then diffuses to induce
apoptosis in neighboring cells.
3.7. Safety evaluation of LPI NPs
Nephrotoxicity, a common pitfall of platinum based drugs, was then evaluated and indicated
that LPI NPs reduced toxicity over free CDDP at the same dose (Fig. 7). Kidneys treated
with LPI NPs showed similar responses to those treated with PBS and no signs of
Guo et al. Page 7






















nephrotoxicity were observed in mice treated with LPI NPs. However, glomeruloscelorsis,
tubular cell atrophy, and cystic dilatation of renal tubes were observed in kidneys from mice
treated with free CDDP at the same dose. Although kidneys were injured at a low dose of
CDDP, BUN assay, which was measured 7 days after the last treatment, indicated injured
kidneys recovered after a week, because there was no significant difference in BUN results
between kidneys from CDDP treated mice and control group (Fig. 8). Pathologic
examination of other major organs in mice that received long-term treatments indicated that
mice treated with LPI NPs suffered no organ damage. AST and ALT in mice treated with
CDDP and LPI NPs fell within the normal range, indicating no significant liver toxicity
(Fig. 8). Although considerable spleen accumulation was observed (Fig. 4), no spleen
toxicity was observed (Fig. 7). This finding can likely be attributed to macrophage uptake of
LPI NPs in the spleen, which is quite resistant to Pt-induced DNA damage due to its strong
repair mechanism [20–22]. Additionally, we have previously shown that macrophages in the
liver, i.e. Kupffer cells, were quite resistant to LPC NPs, which also uses a platinum based
therapeutic [11].
4. Conclusions
The LPI NPs delivery platform was successful in formulating insoluble iodinated CDDP
(CDDP-I) into LPI NPs at a significant drug loading efficiency of 82 wt%. In vivo studies
showed that LPI NPs had comparable or better anti-tumor activity than free CDDP in two
different melanoma xenograft models. LPI NPs exhibited a strong EPR effect and
accumulated at 9.5% ID/g in an A375M tumor model and induced significant apoptosis
without inducing toxicities. The LPI NPs not only showed activity and safety of CDDP-I,
but also provides a promising platform for additional formulations of inorganic drugs that
are both water and oil insoluble into nanoparticles for therapeutic regimens. Additionally,
this platform can be extended as a paradigm for screening and evaluating the anti-cancer
efficacy of inorganic compounds.
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Characterization of CDDP-I cores by TEM (A) and characterization of LPI NPs by TEM (B)
and DLS (C). LPI NPs were negatively stained using uranyl acetate. White arrow indicates
bilayer of LPI NPs.
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IC50 values of LPI NPs in 1205Lu and A375M cells (A). The amount of the Pt drug
associated with A375M cells after incubation with 100 µM CDDP or LPI NPs in 24 well
plates (B). Each bar represents the mean ± SEM of 3 independent experiments. The analysis
of variance is completed using a one-way ANOVA.
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In vitro release of platinum from LPI NPs in 0.1 wt% P85, 50% FBS and PBS at 37 °C.
Data are expressed as mean ± SD (n = 3).
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Pt distribution in A375M tumor bearing mice administered with CDDP and LPI NPs. One
mg/kg of Pt was administered through IV injection. Mice were sacrificed 24 h post IV
injection. The results are displayed as mean ± SEM (error bars) of five animals per group.
The analysis of variance is computed using a one-way ANOVA. ** indicates P < 0.01.
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The effect of CDDP and LPI NPs on growth of 1205Lu (A) and A375M (B) tumors in vivo.
The arrowheads indicate the time of injection. Two and one mg/kg of Pt was administered
weekly via IV injection for 1205Lu and A375M tumor bearing mice respectively. The
results are displayed as mean ± SEM (error bars) of five animals per group. The analysis of
variance was computed using a one-way ANOVA.
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TUNEL assay and detection of CDDP-DNA adduct in an A375M tumor model. The mice
were sacrificed 24 h after receiving a single IV injection of LPI NPs at a dose of 1.0 mg/kg
Pt. The apoptotic tumor cells were detected by the TUNEL assay (A, green); the formation
of CDDP-DNA adducts in tumor cells were detected by CDDP-DNA adduct antibody (B,
green). Cell nuclei were stained with DAPI. The number represents the percentage of
apoptotic cells (A) or CDDP-DNA adduct positive cells (B).
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H&E staining of heart, liver, spleen, lung and kidney tissue from mice that received four
doses of treatment (1 mg/kg each). H&E staining showed LPI NPs did not induce
nephrotoxicity. Circles indicated glomeruloscelorsis; arrows indicated tubular cell atrophy;
asterisk indicated cystic dilatation of renal tubes.
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Liver and kidney functional parameters, AST (aspartate aminotransferase), ALT (alanine
aminotransferase) and BUN (blood urea nitrogen).
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Synthesis of LPI NPs and structure of iodinated cisplatin (CDDP-I).
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